Longevity Travel Splits Into Two Client Asks

Two funding rounds this week underscore how much capital is chasing biometric self-tracking: Swiss blood-pressure wearable Hilo closed a $19M Series B extension, pushing its total past $119M, while toilet-seat health monitor Casana raised $46M betting smart seats become a mainstream diagnostic category. At the same time, Global Wellness News flagged 'longevity architecture' — homes built around biometric monitoring — as a rising trend, alongside a parallel 'unquantified self' backlash, where clients explicitly want to disconnect from tracking altogether. For advisors, this is a segmentation signal, not a single trend: some clients will want data-dense longevity clinics — SHA Wellness, Clinique La Prairie, Lanserhof-style diagnostic intake — while others will ask for an unplugged retreat with no wearables, no scores, no dashboards. Worth clarifying upfront which camp a client falls into before pitching a program.

Skin longevity is emerging as the successor category to anti-aging on spa menus, backed by real capital: L'Oréal's Cell BioPrint diagnostic tool, a $100M-plus longevity venture fund from Beiersdorf, and a $20M raise for Rapalogix. But trend coverage this month also flags 'longevity-washing' — skincare and spa-menu claims that outrun the clinical evidence behind them. For advisors booking destination spas and medical-wellness stays, that's a due-diligence cue: before recommending a 'skin longevity' add-on at a property like SHA, Palace Merano, or Mayrlife, ask what protocol backs the claim — a diagnostic, a peer-reviewed input, a named clinical partnership — versus a menu line simply borrowing the word. Clients paying premium rates for longevity programming will increasingly expect that distinction made for them rather than left to marketing copy.